SONOMA PHARMACEUTICALS INC (SNOA) Stock Overview
USA - NASDAQ:SNOA - US83558L3033 - Common Stock
SNOA Key Statistics, Chart & Performance
The current stock price of SNOA is 4.06 USD. In the past month the price decreased by -15.35%. In the past year, price increased by 27.1%.
SNOA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 44.25 | 676.33B | ||
| JNJ | JOHNSON & JOHNSON | 17.77 | 428.03B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 14.26 | 249.01B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.81 | 236.68B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.56 | 228.01B | ||
| MRK | MERCK & CO. INC. | 10.08 | 193.83B | ||
| PFE | PFIZER INC | 6.96 | 134.18B | ||
| SNY | SANOFI-ADR | 10.11 | 109.92B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.45 | 88.36B | ||
| GSK | GSK PLC-SPON ADR | 8.76 | 79.62B | ||
| ZTS | ZOETIS INC | 22.69 | 62.55B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 50.52 | 46.27B |
Related stock screener links
About SNOA
Company Profile
Sonoma Pharmaceuticals, Inc. is a global healthcare leader in the development and production of stabilized hypochlorous acid (HOCl) products. The company is headquartered in Boulder, Colorado and currently employs 168 full-time employees. The company went IPO on 2007-01-26. The firm is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. The company offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.
Company Info
SONOMA PHARMACEUTICALS INC
5445 Conestoga Court, Suite 150
Boulder COLORADO 30189 US
CEO: Amy Trombly
Employees: 168
Phone: 18007599305
SONOMA PHARMACEUTICALS INC / SNOA FAQ
What is the stock price of SONOMA PHARMACEUTICALS INC today?
The current stock price of SNOA is 4.06 USD. The price decreased by -0.49% in the last trading session.
What is the ticker symbol for SONOMA PHARMACEUTICALS INC stock?
The exchange symbol of SONOMA PHARMACEUTICALS INC is SNOA and it is listed on the Nasdaq exchange.
On which exchange is SNOA stock listed?
SNOA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SONOMA PHARMACEUTICALS INC stock?
7 analysts have analysed SNOA and the average price target is 15.1 USD. This implies a price increase of 271.82% is expected in the next year compared to the current price of 4.06. Check the SONOMA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SONOMA PHARMACEUTICALS INC worth?
SONOMA PHARMACEUTICALS INC (SNOA) has a market capitalization of 6.66M USD. This makes SNOA a Nano Cap stock.
How many employees does SONOMA PHARMACEUTICALS INC have?
SONOMA PHARMACEUTICALS INC (SNOA) currently has 168 employees.
What are the support and resistance levels for SONOMA PHARMACEUTICALS INC (SNOA) stock?
SONOMA PHARMACEUTICALS INC (SNOA) has a support level at 4.07 and a resistance level at 4.25. Check the full technical report for a detailed analysis of SNOA support and resistance levels.
Is SONOMA PHARMACEUTICALS INC (SNOA) expected to grow?
The Revenue of SONOMA PHARMACEUTICALS INC (SNOA) is expected to grow by 11.38% in the next year. Check the estimates tab for more information on the SNOA EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SONOMA PHARMACEUTICALS INC (SNOA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SNOA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SNOA, evaluating the profitability, health, valuation and growth aspects
- SONOMA PHARMACEUTICALS INC (SNOA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SONOMA PHARMACEUTICALS INC (SNOA) Sales and EPS estimates to see what analysts future expectations are.
- SONOMA PHARMACEUTICALS INC (SNOA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SONOMA PHARMACEUTICALS INC (SNOA) Insider and Institutional Ownership to learn about the owners and their transactions.
- SONOMA PHARMACEUTICALS INC (SNOA) Stock Chart to make your own analysis
- SONOMA PHARMACEUTICALS INC (SNOA) Latest news and press-releases to stay up to date.
Does SONOMA PHARMACEUTICALS INC (SNOA) stock pay dividends?
SNOA does not pay a dividend.
When does SONOMA PHARMACEUTICALS INC (SNOA) report earnings?
SONOMA PHARMACEUTICALS INC (SNOA) will report earnings on 2025-11-05, after the market close.
What is the Price/Earnings (PE) ratio of SONOMA PHARMACEUTICALS INC (SNOA)?
SONOMA PHARMACEUTICALS INC (SNOA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.46).
What is the Short Interest ratio of SONOMA PHARMACEUTICALS INC (SNOA) stock?
The outstanding short interest for SONOMA PHARMACEUTICALS INC (SNOA) is 5.26% of its float. Check the ownership tab for more information on the SNOA short interest.
SNOA Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to SNOA. When comparing the yearly performance of all stocks, SNOA is one of the better performing stocks in the market, outperforming 87.6% of all stocks.
SNOA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SNOA. SNOA may be in some trouble as it scores bad on both profitability and health.
SNOA Financial Highlights
Over the last trailing twelve months SNOA reported a non-GAAP Earnings per Share(EPS) of -2.46. The EPS increased by 46.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.36% | ||
| ROE | -87.65% | ||
| Debt/Equity | 0.03 |
SNOA Forecast & Estimates
7 analysts have analysed SNOA and the average price target is 15.1 USD. This implies a price increase of 271.82% is expected in the next year compared to the current price of 4.06.
For the next year, analysts expect an EPS growth of -96.42% and a revenue growth 11.38% for SNOA